It's a fool's errand to predict specific trial results. A robust quantitative approach to biotech focuses on underlying drivers and base rates. It positions a portfolio so the random, unpredictable nature of trial events plays out favorably over time, guided by factors like valuation and specialist ownership.

Many medtech companies design large trials where a tiny, clinically meaningless response can be statistically significant. Dr. Holman advises entrepreneurs to instead run rigorous trials that prove genuine clinical value, arguing that credible data is the ultimate moat, even if it carries a higher risk of failure.

To frame its trial results positively, Compass Pathways used less stringent definitions for key endpoints. It defined 'clinically meaningful reduction' and 'remission' at levels below the common standard, a tactic that calls into question the true magnitude of the drug's benefit.

The company reports 'overall MMR,' which includes patients maintaining a prior response—a less rigorous metric than 'MMR achievement' (new responses). The CEO notes that discerning investors are focused on the latter, more challenging endpoint, revealing a key area of due diligence for the company's impressive data.

The trial's 57.1% pathologic complete response (pCR) rate is deceptively conservative. It categorized patients who responded well but declined surgery as non-responders, suggesting the treatment's true biological efficacy is even higher than the already impressive reported figure.

The fundamental purpose of any biotech company is to leverage a novel technology or insight that increases the probability of clinical trial success. This reframes the mission away from just "cool science" to having a core thesis for beating the industry's dismal odds of getting a drug to market.

When questioned about discrepancies where a 24-week dose underperformed on the primary endpoint but was strong on secondary ones, the CEO avoided direct comparisons. Instead, he framed the results as a 'totality of evidence' supporting the drug's profile, a key communication tactic for presenting complex or imperfect data positively to investors and regulators.

Experts believe the stark difference in complete response rates (5% vs 30%) between two major ADC trials is likely due to "noise"—variations in patient populations (e.g., more upper tract disease) and stricter central review criteria, rather than a fundamental difference in the therapies' effectiveness.

Ocular Therapeutix's trial prioritized a primary endpoint designed to satisfy FDA requirements for a superiority label—a key regulatory win. However, the CEO stresses that clinicians use different metrics like OCT fluid, where their drug "easily beat Eylea." This highlights a crucial strategy: separate the endpoint needed for approval from the data that drives physician adoption.